Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Secretory Leukocyte Protease Inhibitor Prevents Allergen-Induced Pulmonary Responses in Animal Models of Asthma

Clifford D. Wright, Andrew M. Havill, Scot C. Middleton, Mohammed A. Kashem, Patrice A. Lee, David J. Dripps, Thomas G. O’Riordan, Michael P. Bevilacqua and William M. Abraham
Journal of Pharmacology and Experimental Therapeutics May 1999, 289 (2) 1007-1014;
Clifford D. Wright
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew M. Havill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scot C. Middleton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed A. Kashem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice A. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Dripps
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas G. O’Riordan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael P. Bevilacqua
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William M. Abraham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Secretory leukocyte protease inhibitor (SLPI) is a naturally occurring protein of human airways that exhibits broad spectrum inhibitory activity against mast cell and leukocyte serine proteases implicated in asthma pathology. To assess the potential therapeutic utility of SLPI in this disorder, its effects on antigen-induced pulmonary responses were evaluated. In Ascaris-sensitized sheep, SLPI (3 mg) administered by aerosol daily for 4 days, with the final dose 0.5 h before antigen challenge, reduced the areas under the curve for early- and late-phase bronchoconstriction (73 and 95%, respectively;p < .05 versus control responses). SLPI also inhibited the development of airway hyperresponsiveness to carbachol (84%, p < .05 versus control response) measured 24 h after antigen challenge. In ovalbumin-sensitized guinea pigs, intratracheal administration of SLPI daily for 3 days, with the final dose 1 h before antigen challenge, inhibited the development of airway hyperresponsiveness to histamine with an ED50 of <0.05 mg/kg. Prolonged pharmacodynamic activity of SLPI was observed in both species. In a murine model of atopic asthma, SLPI inhibited leukocyte influx into the airways after chronic allergen challenge. SLPI administered to sheep by the predosing protocol described above also prevented the antigen-induced decrease of tracheal mucus velocity (p < .05). In addition, a single aerosol administration of SLPI (30 mg) to sheep 1 h after antigen challenge inhibited the subsequent late-phase bronchoconstriction and development of hyperresponsiveness and reversed the stimulated decrease in tracheal mucus velocity. These results suggest that SLPI may provide therapeutic intervention against the pathophysiology of asthma and its underlying pathology.

Footnotes

  • Send reprint requests to: Clifford D. Wright, Ph.D., Department of Pharmacology, Amgen, Inc., 1 Amgen Center Drive, Mailstop 15-2-a, Thousand Oaks, CA 91320. E-mail:cwright{at}amgen.com

  • ↵1 Support for this research was provided by Amgen, Inc., Thousand Oaks, CA. This work was presented in abstract form at the 1997 Annual Meeting of the American Thoracic Society.

  • Abbreviations:
    SLPI
    secretory leukocyte protease inhibitor
    pNA
    p-nitroanilide
    BSA
    bovine serum albumin
    RL
    mean pulmonary flow resistance
    Vtg
    thoracic gas volume
    SRL
    specific lung resistance
    PBS
    phosphate-buffered saline
    Penh
    pause enhanced
    Te, total expiratory time
    RT,relaxation time
    PEF, peak expiratory flow
    PIF, peak inspiratory flow
    i.t.
    intratracheal
    • Received October 19, 1998.
    • Accepted January 5, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 2
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Secretory Leukocyte Protease Inhibitor Prevents Allergen-Induced Pulmonary Responses in Animal Models of Asthma
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Secretory Leukocyte Protease Inhibitor Prevents Allergen-Induced Pulmonary Responses in Animal Models of Asthma

Clifford D. Wright, Andrew M. Havill, Scot C. Middleton, Mohammed A. Kashem, Patrice A. Lee, David J. Dripps, Thomas G. O’Riordan, Michael P. Bevilacqua and William M. Abraham
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 1007-1014;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Secretory Leukocyte Protease Inhibitor Prevents Allergen-Induced Pulmonary Responses in Animal Models of Asthma

Clifford D. Wright, Andrew M. Havill, Scot C. Middleton, Mohammed A. Kashem, Patrice A. Lee, David J. Dripps, Thomas G. O’Riordan, Michael P. Bevilacqua and William M. Abraham
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 1007-1014;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
  • Pharmacodynamics of Immunosuppression by Mycophenolic Acid: Inhibition of Both Lymphocyte Proliferation and Activation Correlates with Pharmacokinetics
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics